Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +55

Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?

📅 Biogen is scheduled to report Q2 2026 earnings on July 29 before the market opens.

💰 Consensus estimates peg second-quarter sales at $2.47 billion and EPS at 79 cents.

📉 MS drug sales are expected to decline due to generic competition for Tecfidera and biosimilar pressure on Tysabri.

🚀 Vumerity sales are forecasted to rise driven by strong demand in the United States market.

💊 Skyclarys sales are projected to improve sequentially with growth in markets outside the U.S.

🧠 Alzheimer's collaboration revenues will increase as Leqembi sales continue their global upward trend.

🤝 Biogen closed its acquisition of Apellis Pharmaceuticals adding Empaveli and Syfovre to its portfolio.

💸 The company agreed to acquire RayThera for $1 billion to bolster its immunology pipeline.

⚠️ Q2 earnings will be impacted by IPR&D charges related to the Apellis and TJ Biopharma acquisitions.

📈 Biogen's stock has gained 14.0% year-to-date compared to a 2.2% industry increase.

🏆 The company has beaten earnings estimates for four consecutive quarters with an average surprise of 26.87%.

🔭 Core operating expenses are expected to remain consistent with the first quarter levels.

Bullish Signals
  • Biogen's stock has risen 14.0% year-to-date, significantly outperforming the industry average of 2.2%.
  • The company has a proven track record of beating earnings estimates for four consecutive quarters with an average surprise of 26.87%.
  • Vumerity sales are expected to rise due to strong demand in the United States market.
  • Skyclarys sales are likely to continue improving sequentially backed by demand growth in outside U.S. markets.
  • Zurzuvae sales are expected to benefit from strong demand trends following its launch.
  • Alzheimer's collaboration revenues are projected to rise as Leqembi sales improve sequentially over the past few quarters.
  • Biogen recently acquired Apellis Pharmaceuticals and agreed to acquire RayThera for $1 billion to strengthen its commercial portfolio and pipeline.
Risk Factors
  • Sales of Biogen's MS drugs like Tecfidera are likely to decline due to generic competition globally.
  • Spinraza sales are likely to decline due to lower demand in the U.S. market.
  • Biogen will record IPR&D charges related to the Apellis acquisition and the acquisition of felzartamab rights in China, which will hurt EPS.
  • The company faces rising competitive pressure in the multiple sclerosis market.
Full Analysis
Biogen (BIIB) is set to report second-quarter 2026 earnings on July 29, with analysts expecting a beat based on recent performance where the company exceeded estimates by an average of 21.02% in the last quarter. Consensus estimates project sales of $2.47 billion and earnings of 79 cents per share, though some models suggest higher potential. The company faces headwinds from declining sales in its multiple sclerosis portfolio, specifically Tecfidera due to generic competition globally and Tysabri facing biosimilar pressure in Europe. Conversely, new products like Vumerity are expected to show growth driven by strong U.S. demand, while Skyclarys continues to improve sequentially with international expansion. Biogen's Alzheimer's collaboration revenues are anticipated to rise as Leqembi sales grow globally. The company recently expanded its portfolio through the acquisition of Apellis Pharmaceuticals and a definitive agreement to acquire RayThera for $1 billion to strengthen its immunology pipeline, though these transactions will incur IPR&D charges impacting EPS in the quarter. Despite challenges from generic competition and acquisition-related costs, Biogen's stock has risen 14.0% year-to-date, significantly outperforming the industry average of 2.2%. The company maintains a track record of beating estimates for four consecutive quarters with an average earnings surprise of 26.87%, supported by strong analyst ratings and positive momentum in its new drug launches.